Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$209.79
-1.6%
$232.79
$160.86
$250.74
$13.09B0.39681,134 shs384,010 shs
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$67.41
-0.4%
$70.55
$38.57
$84.94
$13.20B0.972.79 million shs2.13 million shs
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$22.95
-6.3%
$22.89
$13.15
$27.72
$11.46B1.695.50 million shs7.95 million shs
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
$64.03
-4.3%
$62.25
$10.77
$91.00
$3.86B-0.261.07 million shs957,914 shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
+3.61%-1.56%-10.66%-6.27%+23.15%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
+0.46%+5.95%+0.43%-5.20%+73.41%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
+3.43%+3.53%+4.03%+4.45%+75.63%
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
+4.48%+21.18%+3.62%+94.51%+433.73%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$209.79
-1.6%
$232.79
$160.86
$250.74
$13.09B0.39681,134 shs384,010 shs
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$67.41
-0.4%
$70.55
$38.57
$84.94
$13.20B0.972.79 million shs2.13 million shs
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$22.95
-6.3%
$22.89
$13.15
$27.72
$11.46B1.695.50 million shs7.95 million shs
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
$64.03
-4.3%
$62.25
$10.77
$91.00
$3.86B-0.261.07 million shs957,914 shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
+3.61%-1.56%-10.66%-6.27%+23.15%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
+0.46%+5.95%+0.43%-5.20%+73.41%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
+3.43%+3.53%+4.03%+4.45%+75.63%
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
+4.48%+21.18%+3.62%+94.51%+433.73%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
3.00
Buy$295.3940.80% Upside
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
2.85
Moderate Buy$89.5932.90% Upside
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
2.77
Moderate Buy$28.2022.90% Upside
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
2.82
Moderate Buy$131.30105.06% Upside

Current Analyst Ratings Breakdown

Latest ORKA, ASND, BBIO, and ELAN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/9/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Reiterated RatingOutperform
6/3/2026
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
Reiterated RatingBuy
6/3/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Initiated CoverageBuy$104.00
6/2/2026
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
Reiterated RatingOverweight$180.00
5/28/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Boost Price TargetOverweight$94.00 ➝ $98.00
5/28/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Reiterated RatingBuy$110.00
5/26/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
DowngradeOutperformMarket Perform
5/19/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Initiated CoverageNeutral$82.00
5/18/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Initiated CoverageBuy$355.00
5/18/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
UpgradeBuyStrong-Buy
5/18/2026
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
Reiterated RatingBuy$120.00
(Data available from 6/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$814.57M16.07N/AN/A($2.97) per share-70.64
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$502.08M26.30N/AN/A($10.77) per share-6.26
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$4.72B2.43$2.25 per share10.20$13.18 per share1.74
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
N/AN/AN/AN/A$9.69 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-$258M$8.6724.2019.52N/A57.87%N/A-8.37%8/6/2026 (Estimated)
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$724.93M-$3.74N/A293.09N/A-124.42%N/A-65.81%8/4/2026 (Estimated)
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
-$232M-$0.50N/A18.811.55-4.95%7.42%3.66%8/6/2026 (Estimated)
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
-$105.43M-$1.94N/AN/AN/AN/A-26.16%-25.00%8/10/2026 (Estimated)

Latest ORKA, ASND, BBIO, and ELAN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2026Q1 2026
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
-$0.52-$0.48+$0.04-$0.48N/AN/A
5/7/2026Q1 2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$0.21$0.32+$0.11$11.29$362.47 million$285.45 million
5/7/2026Q1 2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$0.70-$0.84-$0.14-$0.84$178.07 million$194.52 million
5/6/2026Q1 2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.34$0.40+$0.06$0.11$1.28 billion$1.37 billion
3/12/2026Q4 2025
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
-$0.61-$0.45+$0.16-$0.45N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/AN/AN/AN/AN/A
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/AN/AN/AN/AN/A
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
N/AN/AN/AN/AN/A
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
0.79
1.00
0.72
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/A
1.52
1.48
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.60
2.16
1.12
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
N/A
23.76
23.76

Institutional Ownership

CompanyInstitutional Ownership
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/A
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
99.85%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
97.48%
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
56.44%

Insider Ownership

CompanyInsider Ownership
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
40.00%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
14.23%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
1.14%
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
23.49%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
1,18962.38 million37.43 millionOptionable
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
400195.86 million167.99 millionOptionable
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
9,400499.45 million493.76 millionOptionable
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
N/A60.31 million46.15 millionN/A

Recent News About These Companies

5 Best Performing Healthcare Stocks So Far in 2026
Halozyme and Oruka sign agreement for Hypercon technology

New MarketBeat Followers Over Time

Media Sentiment Over Time

Ascendis Pharma A/S stock logo

Ascendis Pharma A/S NASDAQ:ASND

$209.79 -3.44 (-1.61%)
Closing price 04:00 PM Eastern
Extended Trading
$210.04 +0.25 (+0.12%)
As of 04:12 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

BridgeBio Pharma stock logo

BridgeBio Pharma NASDAQ:BBIO

$67.41 -0.27 (-0.40%)
Closing price 04:00 PM Eastern
Extended Trading
$66.53 -0.88 (-1.31%)
As of 04:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Elanco Animal Health stock logo

Elanco Animal Health NYSE:ELAN

$22.95 -1.55 (-6.34%)
Closing price 03:59 PM Eastern
Extended Trading
$22.98 +0.04 (+0.17%)
As of 04:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Oruka Therapeutics stock logo

Oruka Therapeutics NASDAQ:ORKA

$64.03 -2.90 (-4.33%)
Closing price 04:00 PM Eastern
Extended Trading
$64.06 +0.03 (+0.04%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.